{"url_path":"/sec/ppcb/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1517681/0001493152-26-023210-index.html","accession_number":"0001493152-26-023210","cik":"0001517681","ticker":"PPCB","issuer_name":"Propanc Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1517681/0001493152-26-023210-index.html","primary_entity_key":"0001517681","primary_entity_name":"Propanc Biopharma, Inc."},"word_count":242,"has_tables":true,"body_markdown":"**Item\n6. Exhibits.**\n\n \n\n**Exhibit**\n\n**Number**\n\n \n**Description**\n\n \n \n \n\n31.1*\n \n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14a or 15d-14(a) under the Securities Exchange Act of 1934, as amended, and adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex31-1.htm)\n\n32.1*\n \n[Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex32-1.htm)\n\n101.INS\n \nXBRL\nInstance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within\nthe Inline XBRL document\n\n101.SCH\n \nInline\nXBRL Taxonomy Extension Schema Document\n\n101.CAL\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB\n \nInline\nXBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document\n\n104*\n \nCover\nPage Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March\n31, 2026, is formatted in Inline XBRL.\n\n \n\n*\nFiled herewith.\n\n \n\n10\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned thereunto duly authorized.\n\n \n\n \n**PROPANC\nBIOPHARMA, INC.**\n\n \n \n \n\nDated:\nMay 14, 2026\nBy:\n*/s/\nJames Nathanielsz*\n\n \nName:\nJames\nNathanielsz\n\n \nTitle:\nChief\nExecutive Officer,\n\n \n \n(Principal\nExecutive Officer)\n\n \n\nDated\nMay 14, 2026\nBy:\n*/s/\nJeannine Zimmerman*\n\n \nName:\nJeannine\nZimmerman\n\n \nTitle:\nChief\nFinancial Officer\n\n \n \n(Principal\nFinancial Officer)\n\n \n\n11"}